Another tick in the box .2022 will be a good year for NSB as they further advance EmtinB while the market realises the huge potential underlying any success.
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
I88 Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”
